Trevena Receives Complete Response Letter for Oliceridine from FDA

November 2, 2018 -- Trevena, Inc. (NASDAQ: TRVN) today announced the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oliceridine.“While we...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news